One of GBT Pharma’s latest projects has seen the team busy re-establishing a presence for Similasan’s eye care range in the Netherlands.
Partnering with the newly founded Dutch subsidiary – Similasan Nederland BV – GBT Pharma has been intensively devising a re-launch programme for this leading brand of allergy eye care products.
Up until 2012, Similasan was the market leading homeopathic eye care brand in the Netherlands. The forthcoming re-launch follows a year long voluntary absence from the Dutch market for the brand.
During this time, GBT Pharma worked closely with Similasan advising on a revised regulatory and customer-facing strategy to support the brand following regulatory changes implemented by the Dutch Ministry of Health in September 2012.
“This is an exciting time to be re-launching Similasan,” comments Gian Trepp, GBT Pharma founder. “Not only is the Dutch market buoyant, after adapting our strategy we will be re-launching four Similasan products as medical devices from June 2014.
“The launch of Similasan’s Dutch branch will support a specific focus on re-establishing this popular brand within key retailers, the independents, drugstores and pharmacies ultimately increasing Similasan’s future role and participation in the Dutch self-care market.
“As well as re-building the Similasan brand in the Netherlands we will be offering in-licensing and product development opportunities to fulfill emerging customer needs in the market,” adds Gian.
Parties interested in listing the Similasan eye care range, or to discuss in-licensing opportunities are invited to contact us: http://www.gbtpharma.com/contact-us